UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2 16, 2023

~~SEAGEN~~Seagen ~~INC~~Inc.

(Exact name of Registrant as specified in its charter)

Delaware

0-32405

91-1874389

~~0-32405~~

~~91-1874389~~

(State or other jurisdictionof incorporation or organization)

(CommissionFile Number)

(I.R.S EmployerIdentification No.)

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S Employer Identification No.)

21823 30th Drive SE

Bothell, Washington 98021

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of class		TradingSymbol(s)	~~Trading Symbol(s)~~	Name of each exchange on which registered		~~Name of each exchange on which registered~~
Common Stock, par value $0.001		SGEN	~~SGEN~~	The Nasdaq Stock Market LLC		~~The Nasdaq Stock Market LLC~~

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company ☐~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2 8.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On August 216, 2023, Seagen Inc. issued a press release announcing ~~financial~~that ~~results~~the ~~for~~Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with Kadcyla® (ado-trastuzumab emtansine) met its ~~second~~primary ~~quarter~~endpoint ~~ended~~of ~~June 30,~~progression-free ~~2023~~survival. AHER2CLIMB-02 ~~copy~~is a global, multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial of tucatinib in combination with ado-trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2-positive metastatic or unresectable breast cancer who have had prior treatment with a taxane and trastuzumab in any setting. Additional information is contained in the press release isdated ~~furnished~~August 16, ~~herewith~~2023, which is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.

~~The~~Item ~~information furnished with this report, including Exhibit 99~~9.1,01 ~~shall~~Financial ~~not~~Statements beand deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filingExhibits.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1		Press Release of Seagen Inc. dated August 16, 2023				~~Press Release of Seagen Inc. dated~~			~~August 2, 2023~~
104		Cover Page Interactive Data File (formatted as Inline XBRL)				~~Cover Page Interactive Data File (formatted in Inline XBRL)~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEAGEN INC.

~~SEAGEN INC.~~

Date:

August 2, 2023

By:

/s/ Todd E. Simpson

Date: August 16, 2023

By:

/s/ Jean I. Liu

Todd E. Simpson

Jean I. Liu

Chief Financial Officer

Chief Legal Officer

Filing Compare · Seagen Inc.